ES2964630T3 - Derivados de xantina sustituidos - Google Patents

Derivados de xantina sustituidos Download PDF

Info

Publication number
ES2964630T3
ES2964630T3 ES19820718T ES19820718T ES2964630T3 ES 2964630 T3 ES2964630 T3 ES 2964630T3 ES 19820718 T ES19820718 T ES 19820718T ES 19820718 T ES19820718 T ES 19820718T ES 2964630 T3 ES2964630 T3 ES 2964630T3
Authority
ES
Spain
Prior art keywords
mmol
mixture
added
esi
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19820718T
Other languages
English (en)
Spanish (es)
Inventor
Kai Gerlach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Hydra Biosciences LLC
Original Assignee
Boehringer Ingelheim International GmbH
Hydra Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Hydra Biosciences LLC filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2964630T3 publication Critical patent/ES2964630T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES19820718T 2018-12-12 2019-12-10 Derivados de xantina sustituidos Active ES2964630T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212060 2018-12-12
PCT/EP2019/084375 WO2020120450A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (1)

Publication Number Publication Date
ES2964630T3 true ES2964630T3 (es) 2024-04-08

Family

ID=64665184

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19820718T Active ES2964630T3 (es) 2018-12-12 2019-12-10 Derivados de xantina sustituidos

Country Status (18)

Country Link
US (2) US11198696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3894410B1 (cg-RX-API-DMAC7.html)
JP (1) JP7502299B2 (cg-RX-API-DMAC7.html)
KR (1) KR102877857B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166151B (cg-RX-API-DMAC7.html)
AU (1) AU2019396499B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008316A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001509A1 (cg-RX-API-DMAC7.html)
DK (1) DK3894410T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2964630T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064908T2 (cg-RX-API-DMAC7.html)
IL (1) IL283768B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007019A (cg-RX-API-DMAC7.html)
PH (1) PH12021551345A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894410T3 (cg-RX-API-DMAC7.html)
TW (1) TWI825243B (cg-RX-API-DMAC7.html)
WO (1) WO2020120450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
KR20250141831A (ko) * 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370372B (es) 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
EP3180340B1 (en) 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
JP7114702B2 (ja) * 2017-07-11 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規置換キサンチン誘導体
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted

Also Published As

Publication number Publication date
PL3894410T3 (pl) 2024-03-18
HUE064908T2 (hu) 2024-04-28
BR112021008316A2 (pt) 2021-08-03
KR20210102955A (ko) 2021-08-20
US11198696B2 (en) 2021-12-14
CN113166151A (zh) 2021-07-23
DK3894410T3 (da) 2023-11-27
IL283768A (en) 2021-07-29
CN113166151B (zh) 2023-12-01
TWI825243B (zh) 2023-12-11
JP7502299B2 (ja) 2024-06-18
CA3119229A1 (en) 2020-06-18
KR102877857B1 (ko) 2025-10-29
EP3894410B1 (en) 2023-10-11
EP3894410A1 (en) 2021-10-20
TW202039495A (zh) 2020-11-01
US20200190093A1 (en) 2020-06-18
MX2021007019A (es) 2021-09-10
IL283768B1 (en) 2024-01-01
US20220177479A1 (en) 2022-06-09
WO2020120450A1 (en) 2020-06-18
CL2021001509A1 (es) 2021-12-17
PH12021551345A1 (en) 2022-05-11
AU2019396499A1 (en) 2021-05-27
AU2019396499B2 (en) 2024-10-10
IL283768B2 (en) 2024-05-01
JP2022512373A (ja) 2022-02-03
EA202191588A1 (ru) 2021-10-18

Similar Documents

Publication Publication Date Title
ES2903268T3 (es) Derivados de xantina sustituida
JP5856064B2 (ja) 治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物
BR122021004509B1 (pt) Sais de inibidor de pi3k e processos para seu preparo
WO2020097609A1 (en) Gpr139 receptor modulators
US20220177479A1 (en) Novel substituted xanthine derivatives
EP3894409B1 (en) Substituted xanthine derivatives
CA3119229C (en) Substituted xanthine derivatives
EA043969B1 (ru) Замещенные ксантиновые производные
BR112019025611B1 (pt) Compostos derivados de xantina substituídos e sais dos mesmos
HK40025200B (en) Substituted xanthine derivatives
HK40025200A (en) Substituted xanthine derivatives